CHEMOMAB Granted U.S. Patent #12018074: Anti CCL24 (eotaxin2) antibodies for use in the treatment of hepatic diseases
Portfolio Pulse from Benzinga Newsdesk
CHEMOMAB has been granted U.S. Patent #12018074 for its Anti CCL24 (eotaxin2) antibodies, which are intended for use in the treatment of hepatic diseases.
June 25, 2024 | 7:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CHEMOMAB has received U.S. Patent #12018074 for its Anti CCL24 (eotaxin2) antibodies, which are designed for the treatment of hepatic diseases. This patent could enhance the company's intellectual property portfolio and potentially lead to new treatment options.
The granting of the patent strengthens CHEMOMAB's intellectual property portfolio, potentially leading to new treatment options and enhancing the company's market position. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100